易明医药
(002826)
| 流通市值：15.17亿 | | | 总市值：16.44亿 |
| 流通股本：1.76亿 | | | 总股本：1.91亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 260,480,491.38 | 385,855,732.02 | 227,588,913.27 | 206,587,191.67 |
| 应收票据及应收账款 | 44,356,340.48 | 38,285,617.41 | 139,385,203.21 | 106,126,345.82 |
| 其中：应收票据 | 173,700 | 9,131,590.43 | - | 9,306,660 |
| 应收账款 | 44,182,640.48 | 29,154,026.98 | 139,385,203.21 | 96,819,685.82 |
| 预付款项 | 6,123,212.17 | 976,621.42 | 15,792,645.58 | 6,771,540.12 |
| 其他应收款合计 | 4,150,915.4 | 5,372,018.69 | 12,153,505.34 | 31,480,611.4 |
| 存货 | 40,396,718.93 | 58,968,753.01 | 54,728,961.23 | 50,981,529.77 |
| 其他流动资产 | 174,142.03 | 211,581.68 | 183,748.27 | 119,068.02 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 505,681,820.39 | 489,670,324.23 | 519,832,976.9 | 552,217,671.83 |
| 非流动资产: | | | | |
| 长期股权投资 | 42,561,001.26 | 42,567,473.78 | 42,455,625.95 | 43,354,800 |
| 固定资产 | 344,097,611.93 | 349,154,247.92 | 353,232,755.27 | 356,891,684.64 |
| 在建工程 | 1,131,245.03 | - | - | - |
| 无形资产 | 24,489,334.88 | 25,907,444.36 | 26,806,028.11 | 28,133,814.99 |
| 商誉 | 16,668,928.89 | 16,668,928.89 | 36,472,534.89 | 36,472,534.89 |
| 长期待摊费用 | - | - | 446,112.24 | 892,224.45 |
| 递延所得税资产 | 3,643,633.73 | 3,512,158.67 | 4,567,468.59 | 4,480,468.12 |
| 其他非流动资产 | 269,275 | 263,025 | 143,025 | 159,525 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 432,861,030.72 | 438,073,278.62 | 464,123,550.05 | 470,385,052.09 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 938,542,851.11 | 927,743,602.85 | 983,956,526.95 | 1,022,602,723.92 |
| 流动负债: | | | | |
| 短期借款 | 11,000,000 | 11,010,561.11 | 10,000,000 | 50,000,000 |
| 应付票据及应付账款 | 113,783,355.5 | 106,042,931.08 | 148,844,390.2 | 131,272,092.82 |
| 应付账款 | 113,783,355.5 | 106,042,931.08 | 148,844,390.2 | 131,272,092.82 |
| 合同负债 | 1,415,740.5 | 3,510,131.42 | 924,599.79 | 1,147,103.63 |
| 应付职工薪酬 | 7,999,735.22 | 11,205,572.96 | 7,151,916.68 | 10,148,872.61 |
| 应交税费 | 12,204,213.22 | 5,217,082.47 | 8,557,247.44 | 8,965,439.13 |
| 其他应付款合计 | 31,150,758.1 | 33,637,469.81 | 40,675,073.04 | 44,197,246.27 |
| 其他流动负债 | 184,046.24 | 456,317.06 | 120,197.94 | 149,123.45 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 177,737,848.78 | 171,080,065.91 | 216,273,425.09 | 245,879,877.91 |
| 非流动负债: | | | | |
| 预计负债 | - | - | 1,862,018 | 1,862,018 |
| 递延收益 | 6,379,598.85 | 6,604,315.46 | 6,835,407.42 | 7,043,128.96 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 6,379,598.85 | 6,604,315.46 | 8,697,425.42 | 8,905,146.96 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 184,117,447.63 | 177,684,381.37 | 224,970,850.51 | 254,785,024.87 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 190,677,750 | 190,677,750 | 190,677,750 | 190,677,750 |
| 资本公积 | 232,661,362.96 | 232,661,362.96 | 232,661,362.96 | 232,661,362.96 |
| 减:库存股 | 24,506,692.01 | - | - | - |
| 其他综合收益 | 342,102.61 | 296,573.71 | 971,329.4 | 1,355,819.16 |
| 专项储备 | 3,877,200.46 | 3,100,583.4 | 2,678,125.11 | 1,805,887.74 |
| 盈余公积 | 20,860,834.15 | 20,860,834.15 | 20,860,834.15 | 20,860,834.15 |
| 未分配利润 | 325,319,740.9 | 297,420,661.35 | 305,922,134.56 | 315,182,708.4 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 749,232,299.07 | 745,017,765.57 | 753,771,536.18 | 762,544,362.41 |
| 少数股东权益 | 5,193,104.41 | 5,041,455.91 | 5,214,140.26 | 5,273,336.64 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 754,425,403.48 | 750,059,221.48 | 758,985,676.44 | 767,817,699.05 |
| 负债和股东权益合计 | 938,542,851.11 | 927,743,602.85 | 983,956,526.95 | 1,022,602,723.92 |
| 公告日期 | 2024-04-26 | 2024-04-26 | 2023-10-30 | 2023-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |